EUROPEAN UNION

NXP, eleQtron and ParityQC Reveal their First Quantum Computing Demonstrator for the DLR Quantum Computing Initiative

Retrieved on: 
Giovedì, Maggio 30, 2024
Computer, DLR, Algorithm, Ecosystem, NXP, QCI, BMWK, Larry, Weather, Research, NXPI, MAGIC, Architecture, Quantum, Software, Environment, European, Television

NXP, eleQtron and ParityQC bring together leading knowledge of quantum computing, software and long-standing industry expertise to develop and build the first ion-trap based quantum computer demonstrator made entirely in Germany.

Key Points: 
  • NXP, eleQtron and ParityQC bring together leading knowledge of quantum computing, software and long-standing industry expertise to develop and build the first ion-trap based quantum computer demonstrator made entirely in Germany.
  • The DLR Quantum Computing Initiative has the potential to become something truly great, and our pioneering MAGIC-based quantum computer lays the foundation for a vibrant ecosystem.
  • As Germany's first quantum computing hardware company, we are proud to bring research excellence into the real world.”
    “To achieve a leading international position in quantum computing, we need a strong quantum computing ecosystem.
  • The QSea I demonstrator is an important step for the DLR Quantum Computing Initiative and for Hamburg.

Transaction in Own Shares

Retrieved on: 
Giovedì, Maggio 30, 2024
Withdrawal, Listing Rules, Market abuse, Financial Services Act, Shell, European, BNP, Security (finance)

These share purchases form part of the on- and off-market limbs of the Company's existing share buy-back programme previously announced on 2 May 2024.

Key Points: 
  • These share purchases form part of the on- and off-market limbs of the Company's existing share buy-back programme previously announced on 2 May 2024.
  • In respect of this programme, BNP PARIBAS Financial Markets SNC will make trading decisions in relation to the securities independently of the Company for a period from 2 May 2024 up to and including 26 July 2024.
  • The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market.
  • The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein.

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Retrieved on: 
Venerdì, Maggio 31, 2024
General Health, Other Health, Health, Genetics, Pharmaceutical, Patient, Thrombotic thrombocytopenic purpura, ADAMTS13, Thrombocytopenia, TTP, Safety, European, Stroke, Marketing, European Commission, EMA, Toll, Mortality, Enzyme replacement therapy, Microangiopathic hemolytic anemia, Committee, CHMP

Takeda ( TSE:4502/NYSE:TAK ) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval, under exceptional circumstances, of recombinant ADAMTS13 (rADAMTS13) for the treatment of ADAMTS13 deficiency in children and adult patients with cTTP.

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval, under exceptional circumstances, of recombinant ADAMTS13 (rADAMTS13) for the treatment of ADAMTS13 deficiency in children and adult patients with cTTP.
  • The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for rADAMTS13 throughout the European Union (EU).
  • “With this positive opinion for recombinant ADAMTS13, we are one step closer to offering patients in the EU the first treatment specifically indicated for cTTP.
  • Data from this trial ( NCT03393975 ) were published in The New England Journal of Medicine in May 2024. rADAMTS13 is also being investigated in adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP), the acquired form of TTP, in an ongoing Phase 2b trial ( NCT05714969 ).

e4life, the New Frontier in the Battle Against Viruses Has Arrived in the United Kingdom Thanks to a Patented Italian Device Which Uses Electromagnetic Waves to Inactivate Them

Retrieved on: 
Venerdì, Maggio 31, 2024
Data Management, Biotechnology, Technology, Other Health, Health, Biometrics, Health Technology, Other Technology, Medical Devices, Infectious Diseases, COVID-19, Lendlease, CE, Nature, ELT, HERA, Laboratory, Celio, Biomedicine, University, Light, Bacteria, Joint Research Centre, Publication, Animal, European Commission, Atmosphere, Research, Plasma protein binding, ERS, Attention, Hospital, JRC, Multimedia, Quality of life, European, Futures studies, Vaccine

E4life is an Italian start-up resulting from the joint venture between ELT Group, world leader in Electronic Defence systems and Lendlease, which specializes in large-scale urban regeneration projects.

Key Points: 
  • E4life is an Italian start-up resulting from the joint venture between ELT Group, world leader in Electronic Defence systems and Lendlease, which specializes in large-scale urban regeneration projects.
  • This includes droplets up to 10 microns, with an efficiency rate of more than 90% and a propagation speed equal to that of light, with an almost instantaneous effect.
  • This innovative technology has been included and positively evaluated in the JRC – HERA technology foresight study.
  • Thanks to constant and continuous scientific research, the devices will be able to neutralise an ever-increasing number of pathogens determined by both type and quantity.

Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions to Comply with IVDR Regulation

Retrieved on: 
Venerdì, Maggio 31, 2024
Software, Research, General Health, Data Management, Medical Devices, Technology, Genetics, Health Technology, Science, Biotechnology, Medical Supplies, Health, IVDR, Cytogenetics, Disorder, Chromosome, Safety, CMA, Genome, Thermo Fisher Scientific, Chas, CMAS, European, Medical device

Thermo Fisher Scientific Inc., the world leader in serving science, announced today that the Applied Biosystems™ CytoScan™ Dx Assay and Applied Biosystems™ Chromosomal Analysis Suite (ChAS) Dx software now comply with In Vitro Diagnostic Regulations (IVDR) 2017/746 in the European Union.

Key Points: 
  • Thermo Fisher Scientific Inc., the world leader in serving science, announced today that the Applied Biosystems™ CytoScan™ Dx Assay and Applied Biosystems™ Chromosomal Analysis Suite (ChAS) Dx software now comply with In Vitro Diagnostic Regulations (IVDR) 2017/746 in the European Union.
  • These compliance updates will enable cytogenetics testing laboratories to adapt to the latest medical device safety and efficacy frameworks and conformity assessments.
  • “Thermo Fisher’s unparalleled commitment to driving innovation in chromosomal microarrays has led to advancement of cytogenetic testing capabilities,” said Kevin Lowitz, vice president and general manager, microarray, at Thermo Fisher Scientific.
  • ChAS Dx is a powerful, intuitive software that simplifies cytogenetic analysis, visualization, and reporting of chromosomal aberrations across the genome.

DoseMeRx Submitted a Formal Application for CE Certification Under MDR, Ensuring Uninterrupted Service and Safety for Customers and Patients

Retrieved on: 
Giovedì, Maggio 30, 2024
Technology, Hospitals, Security, Health Technology, Software, Health, Pharmaceutical, General Health, Data Management, CE, Patient, Patient safety, CCO, Medical device, MDD, Authorization, Safety, MDR, Certification

Regulatory Compliance: DoseMeRx, which previously held a Directives Certificate under the Medical Device Directive (MDD), has now submitted a formal application for CE certification under MDR ensuring continued market presence and regulatory compliance.

Key Points: 
  • Regulatory Compliance: DoseMeRx, which previously held a Directives Certificate under the Medical Device Directive (MDD), has now submitted a formal application for CE certification under MDR ensuring continued market presence and regulatory compliance.
  • Patient Safety: The submission of our MDR application to the notified body reaffirms our dedication to patient safety and the effectiveness of our precision dosing software.
  • Uninterrupted Service: Our customers can be confident that DoseMeRx will continue to deliver reliable and precise dosing recommendations, with no interruptions or disruptions in service.
  • “We are thrilled to have successfully navigated the transition to the MDR framework,” said Paul Edwards, CEO, DoseMe.

The Central and Eastern Europe Fund, Inc. Provides Update on Developments Regarding Russian Holdings

Retrieved on: 
Giovedì, Maggio 30, 2024
Banking, Asset Management, Professional Services, Finance, Central bank, Terrorism, Risk, Moscow Exchange, Fund, Investment, Suite, Sale, System, Freezing, Government, Nature, War, Cryptocurrency

The Fund also confirmed that management continues to welcome suggestions from stockholders regarding its holdings of Russian securities and potential options for maximization of stockholder value with respect to such holdings.

Key Points: 
  • The Fund also confirmed that management continues to welcome suggestions from stockholders regarding its holdings of Russian securities and potential options for maximization of stockholder value with respect to such holdings.
  • Such suggestions may be sent to Secretary, The Central and Eastern Europe Fund, Inc., C/O DWS Investment Management Americas, Inc., 100 Summer Street, Suite 800, Boston, MA 02110.
  • The Central and Eastern Europe Fund, Inc. is non-diversified and can take larger positions in fewer issues, increasing its potential risk.
  • The various sanctions have adversely affected, and may continue to adversely affect, not only the Russian economy, but also the economies of many countries in Europe, including countries in Central and Eastern Europe.

Yourway Hosts Symposium and Networking Event in Celebration of its Flagship GMP Depot Opening in Dublin

Retrieved on: 
Giovedì, Maggio 30, 2024
Medical Devices, Medical Supplies, FDA, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Oncology, Clinical trial, Messenger, Therapy, Drug development, European, Gene editing, GMP, Vaccine

“The EU is a critical region for new drug development, and Yourway is committed to providing full support for biotech and biopharma in the region,” commented Gulam Jaffer, founder and president of Yourway.

Key Points: 
  • “The EU is a critical region for new drug development, and Yourway is committed to providing full support for biotech and biopharma in the region,” commented Gulam Jaffer, founder and president of Yourway.
  • “The strategic location of our EU flagship GMP depot is a key part of Yourway’s network in the region.
  • We’re proud to host this event and deepen our ties within the Dublin area specifically, and the EU in general.”
    Yourway’s Dublin GMP depot, with over 12,000 pallet locations over various temperatures, was specifically designed to meet the diverse and specific needs of the EU.
  • To date, Yourway has invested millions of euros in the Dublin facility, and, with its opening, brought significant employment opportunities to the area.

GoldenTree Asset Management Announces Closing of $500 Million CLO Under GLM Strategy

Retrieved on: 
Giovedì, Maggio 30, 2024
Asset Management, Professional Services, Finance, CLO, BofA Securities, GoldenTree Asset Management, Lisp (programming language), Investment, GLM, AAA, Morgan Stanley, Wells Fargo, Appellate court

GLM III, LP (“GLM III”) and its affiliated investment manager GoldenTree Asset Management LP (along with other affiliated investment managers “GoldenTree”), announced the closing of a $500 million collateralized loan obligation (“CLO”) to be managed by GLM III.

Key Points: 
  • GLM III, LP (“GLM III”) and its affiliated investment manager GoldenTree Asset Management LP (along with other affiliated investment managers “GoldenTree”), announced the closing of a $500 million collateralized loan obligation (“CLO”) to be managed by GLM III.
  • With the closing of this CLO, GoldenTree Loan Management US CLO 20 (“GLM US CLO 20”), GoldenTree has issued 26 CLOs totaling over $14 billion under its GLM CLO strategy.
  • Since its inception in January 2017, the GLM strategy was intended to be compliant with applicable Risk Retention regulations.
  • The syndicate globally distributed the rated notes issued by the CLO, while GLM III invested in the CLO’s equity.

Merus Announces Pricing of Upsized Public Offering of Common Shares

Retrieved on: 
Giovedì, Maggio 30, 2024
Investment, Jefferies, EEA, BMO Capital Markets, Form, Attention, Madison Avenue, BofA Securities, European Economic Area, Telephone, Sale, Communication, Security (finance), Finance, Advertising, Jefferies Group, S-3, SVB Securities, State Street, FSMA, Person, Floor, Prospectus, Guggenheim Partners, File

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an upsized underwritten public offering of 7,550,000 common shares, at a public offering price of $53.00 per share (the “Offer Shares”).

Key Points: 
  • UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an upsized underwritten public offering of 7,550,000 common shares, at a public offering price of $53.00 per share (the “Offer Shares”).
  • Merus also granted the underwriters a 30-day option to purchase up to an additional 1,132,500 common shares (the “Option Shares” and together with the Offer Shares, the “Shares”).
  • All of the shares in the offering are to be sold by Merus.
  • Jefferies, BofA Securities, Leerink Partners, Guggenheim Securities and BMO Capital Markets are acting as joint book-running managers for the offering.